Hepatitis C virus immunogenic compositions and methods of use thereof
AssigneesThe Governors of the University of Alberta, Helmholtz Center for Infection Research
InventorsMichael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
Life of this patent
Estimating the term…
Abstract
The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
Claims18
An immunogenic composition comprising:
- a) a hepatitis C virus (HCV) E1 polypeptide, an HCV E2 polypeptide, or an HCV E1/E2 heterodimer;
- and
- b) a cyclic dinucleotide (CDN).
An immunogenic composition comprising:
- a) one or more nucleic acids comprising nucleotide sequences encoding a hepatitis C virus (HCV) E1 polypeptide, an HCV E2 polypeptide, or an HCV E1/E2 heterodimer;
- and
- b) a cyclic dinucleotide.
An immunogenic composition comprising:
- a) a hepatitis C virus (HCV) E1 polypeptide, an HCV E2 polypeptide, or an HCV E1/E2 heterodimer, or one or more nucleic acids comprising nucleotide sequences encoding the HCV E1 polypeptide, the HCV E2 polypeptide, or the HCV E1/E2 heterodimer;
- and
- b) an archaeosome comprising at least one polar synthetic lipid, wherein the at least one polar synthetic lipid comprises at least one carbohydrate or anionic group linked by covalent bonding to at least one free hydroxyl group of an archaeal core lipid.
Dependencies are inferred from the claim text.